Brokerages predict that Cascadian Therapeutics Inc (NASDAQ:CASC) will report ($0.29) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Cascadian Therapeutics’ earnings. Cascadian Therapeutics posted earnings per share of ($0.47) in the same quarter last year, which would suggest a positive year over year growth rate of 38.3%. The business is expected to announce its next earnings report on Thursday, March 8th.
On average, analysts expect that Cascadian Therapeutics will report full-year earnings of ($1.27) per share for the current year, with EPS estimates ranging from ($1.52) to ($1.14). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.18) per share, with EPS estimates ranging from ($1.22) to ($1.16). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Cascadian Therapeutics.
CASC has been the topic of several research analyst reports. Zacks Investment Research downgraded Cascadian Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Raymond James Financial downgraded Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 31st. BidaskClub downgraded Cascadian Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Finally, ValuEngine upgraded Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $5.63.
Shares of Cascadian Therapeutics (CASC) remained flat at $$10.00 during trading on Friday. 473,978 shares of the stock traded hands, compared to its average volume of 1,131,793. Cascadian Therapeutics has a 1-year low of $3.18 and a 1-year high of $10.21. The firm has a market capitalization of $506.11, a PE ratio of -7.47 and a beta of 3.79.
ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Anticipate Cascadian Therapeutics Inc (CASC) Will Post Earnings of -$0.29 Per Share” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2018/03/14/zacks-analysts-anticipate-cascadian-therapeutics-inc-casc-will-post-earnings-of-0-29-per-share-2.html.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.